Fig. 6: Targeting MTCH1 promoted the antitumor activity of Sorafenib.

A Relative cell viability of MTCH1^WT (n = 2) and MTCH1^KO (n = 3) HeLa clones treated with different concentrations (0, 4, 8, 12, 16, 20, 24, 28, 32 µM) of Sorafenib for 24 h. B Relative cell viability of MTCH1^WT (n = 2) and MTCH1^KO (n = 3) HeLa clones treated with 20 µM Sorafenib for different time (0, 12, 24, 36, 48 h). C Representative image of nude mice with tumor from different MTCH1^WT and MTCH1^KD HeLa cells implantation or treatment groups (n = 5). D Representative image of tumors from different MTCH1^WT and MTCH1^KD HeLa cells implantation or treatment groups of nude mice (n = 5). E The tumor volume of different MTCH1^WT and MTCH1^KD HeLa cells implantation or treatment groups of nude mice with time (n = 5). F The tumor weight of different MTCH1^WT and MTCH1^KD HeLa cells implantation or treatment groups of nude mice (n = 5). Data were presented as mean ± SEM of at least 3 independent replicates (***P < 0.001) and analyzed by one-way ANOVA with Tukey’s multiple comparisons test or unpaired t-test.